Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 17

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers

Neal, Adam, Lai, Tiffany, Singh, Tanya, Rahseparian, Neela, Grogan, Tristan, Elashoff, David, Scott, Peter, Pellegrini, Matteo, Memarzadeh, Sanaz · 2021 · Cancers

Abstract

Ovarian malignancies are a leading cause of cancer-related death for US women. High-grade serous ovarian carcinomas (HGSOCs), the most common ovarian cancer subtype, are aggressive tumors with poor outcomes. Mutations in TP53 are common in HGSOCs, with a subset resulting in p53 aggregation and misregulation. ReACp53 is a peptide designed to inhibit mutant p53 aggregation and has been shown efficacious in targeting cancer cells in vitro and in vivo. As p53 regulates apoptosis, combining ReACp53 with carboplatin represents a logical therapeutic strategy. The efficacy of this combinatorial approach was tested in eight ovarian cancer cell lines and 10 patient HGSOC samples using an in vitro organoid drug assay, with the SynergyFinder tool utilized for calculating drug interactions. Results demonstrate that the addition of ReACp53 to carboplatin enhanced tumor cell targeting in the majority of samples tested, with synergistic effects measured in 2 samples, additivity measured in 14 samples, and antagonism measured in 1 sample. This combination was found to be synergistic in OVCAR3 ovarian cancer cells in vitro through enhanced apoptosis, and survival of mice bearing OVCAR3 intraperitoneal xenografts was extended when treated with the addition of ReACp53 to carboplatin versus carboplatin alone. Results suggest that carboplatin and ReACp53 may be a potential strategy in targeting a subset of HGSOCs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers13235908

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 27

  1. Siegel, 2021, Cancer Statistics, 2021, CA Cancer J. Clin., 71, 7, 10.3322/caac.21654 · DOI · Paper page
  2. Kurman, 2008, Pathogenesis of Ovarian Cancer: Lessons from Morphology and Molecular Biology and Their Clinical Implications, Int. J. Gynecol. Pathol., 27, 151
  3. Berek, 2018, Cancer of the Ovary, Fallopian Tube, and Peritoneum, Int. J. Gynecol. Obstet., 143, 59, 10.1002/ijgo.12614 · DOI · Paper page
  4. Armstrong, 2019, NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019, J. Natl. Compr. Cancer Netw., 17, 896, 10.6004/jnccn.2019.0039 · DOI · Paper page
  5. (2011). Cancer Genome Atlas Research Network Integrated Genomic Analyses of Ovarian Carcinoma. Nature, 474, 609–615. · DOI · Paper page
  6. Gerstung, 2020, The Evolutionary History of 2658 Cancers, Nature, 578, 122, 10.1038/s41586-019-1907-7 · DOI · Paper page
  7. Lee, 2007, A Candidate Precursor to Serous Carcinoma That Originates in the Distal Fallopian Tube, J. Pathol., 211, 26, 10.1002/path.2091 · DOI · Paper page
  8. Kindelberger, 2007, Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship, Am. J. Surg. Pathol., 31, 161, 10.1097/01.pas.0000213335.40358.47 · DOI · Paper page
  9. Lane, 1992, P53, Guardian of the Genome, Nature, 358, 15, 10.1038/358015a0 · DOI · Paper page
  10. Hientz, 2017, The Role of P53 in Cancer Drug Resistance and Targeted Chemotherapy, Oncotarget, 8, 8921, 10.18632/oncotarget.13475 · DOI · Paper page
  11. Robles, 2010, Clinical Outcomes and Correlates of TP53 Mutations and Cancer, Cold Spring Harb. Perspect. Biol., 2, a001016, 10.1101/cshperspect.a001016 · DOI · Paper page
  12. Zhang, 2020, Therapeutic Potential of ReACp53 Targeting Mutant P53 Protein in CRPC, Prostate Cancer Prostatic Dis., 23, 160, 10.1038/s41391-019-0172-z · DOI · Paper page
  13. Palanikumar, 2021, Protein Mimetic Amyloid Inhibitor Potently Abrogates Cancer-Associated Mutant P53 Aggregation and Restores Tumor Suppressor Function, Nat. Commun, 12, 3962, 10.1038/s41467-021-23985-1 · DOI · Paper page
  14. Lei, 2021, Molecular Dynamics Study on the Inhibition Mechanisms of ReACp53 Peptide for P53–R175H Mutant Aggregation, Phys. Chem. Chem. Phys., 23, 23032, 10.1039/D1CP03094A · DOI · Paper page
  15. Wang, 2017, Multisite Aggregation of P53 and Implications for Drug Rescue, Proc. Natl. Acad. Sci. USA, 114, E2634
  16. Kanapathipillai, M. (2018). Treating P53 Mutant Aggregation-Associated Cancer. Cancers, 10. · DOI · Paper page
  17. Nguyen, H.T.L., and Soragni, A. (2020). Patient-Derived Tumor Organoid Rings for Histologic Characterization and High-Throughput Screening. STAR Protoc., 100056. · DOI · Paper page
  18. van der Auwera, G.A., and Brian, D. (2020). O’Connor Genomics in the Cloud: Using docker, GATK, and WDL in Terra (1st Edition), O’Rielly Media, Inc.
  19. Bouaoun, 2016, TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data, Hum. Mutat., 37, 865, 10.1002/humu.23035 · DOI · Paper page
  20. Ianevski, 2020, SynergyFinder 2.0: Visual Analytics of Multi-Drug Combination Synergies, Nucleic Acids Res., 48, W488, 10.1093/nar/gkaa216 · DOI · Paper page
  21. Marqus, 2017, Evaluation of the Use of Therapeutic Peptides for Cancer Treatment, J. Biomed. Sci., 24, 21, 10.1186/s12929-017-0328-x · DOI · Paper page
  22. Haley, 2016, Functional Characterization of a Panel of High-Grade Serous Ovarian Cancer Cell Lines as Representative Experimental Models of the Disease, Oncotarget, 7, 32810, 10.18632/oncotarget.9053 · DOI
  23. Siddik, 2003, Cisplatin: Mode of Cytotoxic Action and Molecular Basis of Resistance, Oncogene, 22, 7265, 10.1038/sj.onc.1206933 · DOI · Paper page
  24. Robinson, 2015, Integrative Clinical Genomics of Advanced Prostate Cancer, Cell, 161, 1215, 10.1016/j.cell.2015.05.001 · DOI · Paper page
  25. Zhang, 2017, Proteomic Identification of ERP29 as a Key Chemoresistant Factor Activated by the Aggregating P53 Mutant Arg282Trp, Oncogene, 36, 5473, 10.1038/onc.2017.152 · DOI
  26. Zeng, 2016, Targeting Aggregation of Wilde-Type P53 and Mutant P53 with ReACp53 As a Novel Therapeutic Concept for AML, Blood, 128, 3944, 10.1182/blood.V128.22.3944.3944 · DOI
  27. Patra, 2018, Nano Based Drug Delivery Systems: Recent Developments and Future Prospects, J. Nanobiotechnol., 16, 71, 10.1186/s12951-018-0392-8 · DOI · Paper page

Cited by

See all 17

Metadata

Authors
Neal, A., Lai, T., Singh, T., Rahseparian, N., Grogan, T., Elashoff, D., Scott, P., Pellegrini, M., & Memarzadeh, S.
Affiliations
  • Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
  • Department of Medicine Statistics Core, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
  • Department of Life, Earth, and Environmental Sciences, West Texas A&M University, Canyon, TX 79016, USA
  • UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles, CA 90095, USA
Venue
Cancers
Publisher
MDPI AG
Published
2021-11-24
Volume
13
Issue
23
Pages
5908
ISSN
2072-6694
Cited by
17
References
5
Language
en
Funders
  • American Cancer Society (RSG-14-217-01-TBG)
  • Department of Veterans Affairs (I01BX004651)
  • National Institutes of Health (U54-CA-143931)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers. https://app.cochat.ai/papers/10.3390/cancers13235908
The paper
Neal, A., Lai, T., Singh, T., Rahseparian, N., Grogan, T., Elashoff, D., Scott, P., Pellegrini, M., & Memarzadeh, S. (2021). Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers. Cancers. https://doi.org/10.3390/cancers13235908

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.